VKTX Viking Therapeutics, Inc.
Viking Therapeutics, Inc. (VKTX) is expected to report earnings on October 28, 2026, after the market close. The consensus earnings estimate is a loss of $1.00 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -1.0% since its last earnings release on July 29, 2026.
Sign in or subscribe to unlock sentiment, short interest, and technical indicators.
Whisperings™
About Viking Therapeutics, Inc.
Viking Therapeutics is a clinical-stage biopharmaceutical company focused on the development of novel first-in-class or best-in-class therapies for the treatment of metabolic and endocrine disorders, with three compounds currently in clinical trials.
Sector
Healthcare
Industry
Biotechnology